carmustine and tyrosine

carmustine has been researched along with tyrosine in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (50.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Dröge, W; El Benna, J; Galter, D; Klein, G; Schmid, E	1
Huynh, H; Leong, CT; Nguyen, TH; Ong, CK; Panasci, L; Wong, E	1

Other Studies

2 other study(ies) available for carmustine and tyrosine

Article	Year
Redox priming of the insulin receptor beta-chain associated with altered tyrosine kinase activity and insulin responsiveness in the absence of tyrosine autophosphorylation. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 1998, Volume: 12, Issue:10 Topics: Animals; Antimetabolites; Antineoplastic Agents, Alkylating; Antioxidants; Buthionine Sulfoximine; Carmustine; CHO Cells; Cricetinae; Enzyme Induction; Insulin; Oxidation-Reduction; Phosphoric Monoester Hydrolases; Phosphorylation; Protein-Tyrosine Kinases; Receptor, Insulin; Transfection; Tyrosine	1998
2-Chloroethyl-3-sarcosinamide-1-nitrosourea (SarCNU) exhibits p53-dependent and -independent antiproliferative activity in human nasopharyngeal carcinoma cells in vitro and in vivo. International journal of oncology, 2005, Volume: 27, Issue:4 Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma; Carmustine; Caspase 3; Caspase 7; Caspases; CDC2 Protein Kinase; Cell Cycle; Cell Cycle Proteins; Cell Division; Cell Proliferation; Cell Survival; Cyclin B; Cyclin B1; Cyclin-Dependent Kinase Inhibitor p21; DNA, Complementary; Dose-Response Relationship, Drug; G2 Phase; Genes, p53; Genetic Therapy; Humans; Immunoprecipitation; In Vitro Techniques; Male; Mice; Mice, SCID; Mitosis; Mutation; Nasopharyngeal Neoplasms; Nuclear Proteins; Phosphorylation; Protein-Tyrosine Kinases; Time Factors; Transfection; Tumor Suppressor Protein p53; Tyrosine; Up-Regulation	2005

Article

Year

Redox priming of the insulin receptor beta-chain associated with altered tyrosine kinase activity and insulin responsiveness in the absence of tyrosine autophosphorylation.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 1998, Volume: 12, Issue:10

Topics: Animals; Antimetabolites; Antineoplastic Agents, Alkylating; Antioxidants; Buthionine Sulfoximine; Carmustine; CHO Cells; Cricetinae; Enzyme Induction; Insulin; Oxidation-Reduction; Phosphoric Monoester Hydrolases; Phosphorylation; Protein-Tyrosine Kinases; Receptor, Insulin; Transfection; Tyrosine

1998

2-Chloroethyl-3-sarcosinamide-1-nitrosourea (SarCNU) exhibits p53-dependent and -independent antiproliferative activity in human nasopharyngeal carcinoma cells in vitro and in vivo.

International journal of oncology, 2005, Volume: 27, Issue:4

Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma; Carmustine; Caspase 3; Caspase 7; Caspases; CDC2 Protein Kinase; Cell Cycle; Cell Cycle Proteins; Cell Division; Cell Proliferation; Cell Survival; Cyclin B; Cyclin B1; Cyclin-Dependent Kinase Inhibitor p21; DNA, Complementary; Dose-Response Relationship, Drug; G2 Phase; Genes, p53; Genetic Therapy; Humans; Immunoprecipitation; In Vitro Techniques; Male; Mice; Mice, SCID; Mitosis; Mutation; Nasopharyngeal Neoplasms; Nuclear Proteins; Phosphorylation; Protein-Tyrosine Kinases; Time Factors; Transfection; Tumor Suppressor Protein p53; Tyrosine; Up-Regulation

2005